About four months have passed since my last article, "Merck Proves Why It's Still a Top Pharma Pick," and during that time, its stock price has risen by 5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investmen ...